Journal of Hepatology
Volume 42, Issue 1 , Pages 75-81 , January 2005

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin

  • Marta López-Parra

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Joan Clària

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 93 2275400x2814; fax: +34 93 2275454.
    • ,
  • Esther Titos

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Anna Planagumà

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Marcelina Párrizas

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Jaime L. Masferrer

      Affiliations

    • Pfizer Research and Development, St Louis, MO, USA
    • ,
  • Wladimiro Jiménez

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Vicente Arroyo

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Francisca Rivera

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • ,
  • Joan Rodés

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain

Received 11 June 2004 ,Revised 27 August 2004 ,Accepted 21 September 2004.

References 

  1. Marnett LJ, Kalgutkar AS. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol Sci. 1999;20:465–469
  2. McMurray RW, Hardy KJ. Cox-2 inhibitors: today and tomorrow. Am J Med Sci. 2002;323:181–189
  3. Clària J, Arroyo V. Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins Other Lipid Mediat. 2003;72:19–33
  4. Bosch-Marcé M, Clària J, Titos E, Masferrer JL, Altuna R, Poo JL, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology. 1999;116:1167–1175
  5. López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol. 2002;135:891–900
  6. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J. 2001;15:1622–1624
  7. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275:11397–11403
  8. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002;531:278–284
  9. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418–1423
  10. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J. 2003;17:1547–1549
  11. Planagumà A, Titos E, López-Parra M, Gaya J, Pueyo G, Arroyo V, et al. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J. 2002;16:1937–1939
  12. Tisher CC, Madsen KM. Anatomy of the kidney. In:  Brenner BM,  Rector FC editor. The kidney. Philadelphia, PA: WB Saunders Company; 1991;p. 3–75
  13. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171–1176
  14. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJ, et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest. 1992;90:136–141
  15. Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol. 2001;62:1587–1595
  16. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406–3410
  17. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002;302:18–25
  18. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456
  19. Peters T. Serum albumin. Adv Protein Chem. 1985;37:161–245
  20. Guyton AC, Hall JE. Human physiology and mechanisms of disease. Philadelphia, PA: WB Saunders Company; 1997;
  21. Fitzpatrick FA, Waynalda MA. Albumin-lipid interactions: prostaglandin stability as a probe for characterizing binding sites on vertebrate albumins. Biochemistry. 1981;20:6129–6134
  22. Zoellner H, Hofler M, Beckmann R, Hufnagl P, Vanyek E, Bielek E, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci. 1996;109:2571–2580
  23. Benz M, Werz O, Jacob R, Steinhilber D. pH-Dependent regulation of leukocyte 5-lipoxygenase activity in inflammatory exudates by albumin. Inflamm Res. 1997;46:366–372
  24. Broekman MJ, Eiroa AM, Marcus AJ. Albumin redirects platelet eicosanoid metabolism toward 12(S)-hydroxyeicosatetraenoic acid. J Lipid Res. 1989;30:1925–1932
  25. Dadaian M, Granstrom E, Westlund P. Albumin prevents metabolism of 12-hydroxyeicosatetraenoic acid by leukocytes in vitro. Biochim Biophys Acta. 1996;1303:154–160
  26. Ek BA, Cistola DP, Hamilton JA, Kaduce TL, Spector AA. Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. Biochim Biophys Acta. 1997;1346:75–85
  27. Dadaian M, Westlund P. Albumin modifies the metabolism of hydroxyeicosatetraenoic acids via 12-lipoxygenase in human platelets. J Lipid Res. 1999;40:940–947
  28. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002–1010
  29. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-Del-Árbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409
  30. Martin M, Krichbaum M, Kaever V, Goppelt-Strube M, Resch K. Cyclosporin A suppresses proliferation of renal mesangial cells in culture. Biochem Pharmacol. 1988;37:1083–1088
  31. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int. 1994;45:150–158
  32. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812
  33. Ardaillou R, Baud L, Sraer J. Leukotrienes and other lipoxygenase products of arachidonic-acid synthesized in the kidney. Am J Med. 1986;81:12–22
  34. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383–9387
  35. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271:8919–8924
  36. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405–409
  37. Colmenarejo G, Álvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem. 2001;44:4370–4378
  38. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib. A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225–242
  39. Fitzpatrick FA, Wynalda MA. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem. 1983;258:11713–11718
  40. Person EC, Waite LL, Taylor RN, Scanlan TS. Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12–14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo. Endocrinology. 2001;142:551–556
  41. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum. 2002;46:3159–3167
  42. Morrow JD, Moore KP, Awad JA, Ravenscraft MD, Marini G, Badr KF, et al. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J Lipid Mediat. 1993;6:417–420
  43. Ma YH, Harder DR, Clark JE, Roman RJ. Effects of 12-HETE on isolated dog renal arcuate arteries. Am J Physiol. 1991;261:H451–H456
  44. Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane-B2 and prostaglandin-E2 in the hepatorenal-syndrome. Evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983;84:697–703
  45. Clària J, Kent JD, López-Parra M, Escolar G, Ruiz-del-Árbol L, Ginès P, et al. Effects of celecoxib and naproxen on renal function in patients with cirrhosis and ascites: a double-blind randomized controlled trial. J Hepatol. 2004;40:3–4

☆ The authors state that they did not receive funding from the drug manufacturers of the study. However, they state that one author, Jaime L. Masferrer, is an employee of the company.

PII: S0168-8278(04)00433-7

doi: 10.1016/j.jhep.2004.09.011

Journal of Hepatology
Volume 42, Issue 1 , Pages 75-81 , January 2005

Article Tools

* Image Usage & Resolution